New bladder gel could help patients avoid bladder removal surgery
NCT ID NCT07468851
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment called HS-10566, a gel that delivers the chemotherapy drug gemcitabine directly into the bladder. It is for people with high-risk non-muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. The trial will check if the treatment is safe, tolerable, and effective at controlling the cancer. About 180 adults will take part in this early-phase study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HS-10566 (a gel that delivers the chemotherapy drug gemcitabine directly into the bladder)
What this could lead to
If successful, this could offer a bladder-sparing treatment option for patients with high-risk bladder cancer who cannot or choose not to have their bladder removed.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. The treatment may not work for everyone and could cause side effects from the chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- JL19001 for Bladder Cancer Trial (NCT07483970)
- Liquid Biopsy for Bladder Cancer Re-TURBT Guidan NCT07130578
- Erdafitinib for Bladder Cancer After BCG Failure NCT04172675
- Bladder Cancer Trial: Gem/Docetaxel + Pembrolizu NCT06972615
- Bladder Cancer Gene Therapy Trial (NCT07356791)
- TRAIN Trial: Radiotherapy vs BCG for Bladder Can NCT07268339
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Drum Tower Hospital
Nanjing, 210008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University First Hospital
Beijing, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••